help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 62, No. 4 747-752
doi:10.1210/jcem-62-4-747
Copyright © 1986 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DELMEZ, J. A.
Right arrow Articles by TEITELBAUM, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DELMEZ, J. A.
Right arrow Articles by TEITELBAUM, S. L.

Does Strict Phosphorus Control Precipitate Renal Osteomalacia*

JAMES A. DELMEZ, MICHAEL D. FALLON, HERSCHEL R. HARTER, KEITH A. HRUSKA, EDUARDO SLATOPOLSKY and STEVEN L. TEITELBAUM

Chromalloy American Kidney Center and Renal Division at Washington University Medical Center and the Department of Pathology and Laboratory Medicine The Jewish Hospital at Washington University Medical Center St. Louis, Missouri 63110

Address requests for reprints to: James A. Delmez, M.D., Department of Medicine, Chromalloy American Kidney Center, Washington University School of Medicine, 4949 Barnes Hospital Plaza, St. Louis, Missouri 63110.

Hyperphosphatemia leads to the development of osteitis fibrosa in patients with chronic renal failure. In contrast, crippling osteomalacia may appear in uremic patients who are hypophosphatemic or aluminum intoxicated or who undergo total or subtotal parathyroidectomy. Thus, strict phosphorus control by use of aluminum-containing gels may ameliorate renal osteitis fibrosa, but may potentiate the development of osteomalacia. To evaluate this possibility, we compared the bone histologies of 10 chronic renal hemodialysis patients who consistently maintained predialysis phosphorus levels between 4–5 mg/dl (Strict-P) to those of 46 randomly selected dialysis patients (Random-P).

We found that the Strict-P group had lower circulating immunoreactive PTH (P <0.02) and alkaline phosphatase (P < 0.05) levels and, as expected, less evidence of hyperparathyroid bone disease. On the other hand, the Strict-P patients had osteomalacia, as evidenced by moderate osteoid accumulation and reduced capacity of bone to assume a fluorescent tetracycline label. Furthermore, all Strict-P patients had histological evidence of bone aluminum accumulation. We conclude that maintenance of normal serum P levels with aluminum-containing gels in hemodialysis patients prevents severe hyperparathyroid bone disease. Such treatment, however, is also attended by a moderate degree of aluminum-associated osteomalacia.

* This work was supported in part by NIH Grants AM-09976, AM-11674, AM-07126, and RR-00036, the Shriners Hospital for Crippled Children (St. Louis Unit), and the Jewish Hospital Auxiliary.

Received February 20, 1985.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society